NCT06682000View on ClinicalTrials.gov

Efficacy and Safety of DWC202404 and DWC202314 in Patients with Hypertension

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

186

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions
HypertensionEssential Hypertension
Interventions
DRUG

DWC202404, DWC202314

\- 2 tablet, Oral, Once a day

DRUG

DWC202404, DWC202314P

\- 2 tablet, Oral, Once a day

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY